<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-dexamethasone.xml</id>
  <title>Recalls Watch: Dexamethasone</title>
  <link rel="self" href="https://recalls.watch/feed/substance-dexamethasone.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-11-11T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/100168/</id>
    <title>Victory Medical Center Pharmacy: ALPHA LIPOIC ACID and 41 more</title>
    <link href="https://recalls.watch/recall/fda/100168/"/>
    <updated>2026-11-11T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Processing Controls</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/98388/</id>
    <title>SOMERSET THERAPEUTICS LLC: Dexamethasone Sodium Phosphate Injection</title>
    <link href="https://recalls.watch/recall/fda/98388/"/>
    <updated>2026-03-25T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were above specs for these impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/98181/</id>
    <title>Imprimis NJOF, LLC: Dexamethasone Moxifloxacin and 2 more</title>
    <link href="https://recalls.watch/recall/fda/98181/"/>
    <updated>2026-01-14T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Presence of particulate matter - Glass like particles.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/96699/</id>
    <title>Nubratori, Inc: Dexonto 0.4%</title>
    <link href="https://recalls.watch/recall/fda/96699/"/>
    <updated>2025-05-07T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/94685/</id>
    <title>Eugia US LLC: Dexamethasone Sodium Phosphate injection USP</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=94685"/>
    <updated>2024-06-26T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/94551/</id>
    <title>Imprimis NJOF, LLC: Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free 1mL Single-Use… and 4 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=94551"/>
    <updated>2024-06-05T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Assurance of Sterility</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/65360/</id>
    <title>Lowlite Investments, Inc. D/B/A Olympia Pharmacy: Acetyl-D-Glucosamine w/Chondroitin 200 mg/ml and 104 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=65360"/>
    <updated>2013-07-17T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes</summary>
  </entry>
</feed>
